the_DT use_NN of_IN proportional_JJ reporting_NN ratios_NNS -LRB-_-LRB- PRR_NN 's_POS -RRB-_-RRB- -LRB-_-LRB- 5_CD -RRB-_-RRB- and_CC at_IN the_DT Uppsala_NNP Monitoring_NN Centre_NNP where_WRB Edwards_NNP ,_, Lindquist_NNP ,_, Bate_NNP and_CC others_NNS have_VBP pursued_VBN the_DT use_NN of_IN techniques_NNS based_VBN on_IN Bayesian_JJ neural_JJ networks_NNS =_JJ -_: =[_NN 6_CD -RRB-_-RRB- -_: =_SYM -_: ._.
GlaxoSmithKline_NN -LRB-_-LRB- ``_`` GSK_NNP ''_'' -RRB-_-RRB- and_CC Lincoln_NNP Technologies_NNP -LRB-_-LRB- ``_`` Lincoln_NNP ''_'' -RRB-_-RRB- began_VBD a_DT collaboration_NN in_IN 2001_CD to_TO apply_VB safety_NN data_NNS mining_NN techniques_NNS both_DT to_TO provide_VB direct_JJ leverage_NN in_IN addressing_VBG GSK_NNP 's_POS core_NN business_NN pr_NN
